Extensively Drug-Resistant Tuberculosis: Clinical Trials

23 trials for Extensively Drug-Resistant Tuberculosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

20 completed, 1 recruiting, 1 terminated, 1 unknown. 9 Phase 2, 9 Phase 3, 3 Phase 1, 1 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 29Completed 8, Unknown 1
Phase 39Completed 8, Unknown 1
Phase 13Completed 3
Phase 41Completed 1

Follow Extensively Drug-Resistant Tuberculosis: new trials by email Literature Review of Extensively Drug-Resistant Tuberculosis trials Research Report on Extensively Drug-Resistant Tuberculosis

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Triage Test for All Oral DR-TB Regimen (TRiAD Study)
Xpert® MTB/XDR - Drug Resistant Tuberculosis, MDR-TB
CompletedCentre for the AIDS Programme of Research in South Africa7862022-05-262025-06-26
A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis
Pretomanid, Bedaquiline, moxifloxacin - Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant
Phase 2CompletedGlobal Alliance for TB Drug Development262021-09-162025-01-17
Economic Evaluation of New MDR TB Regimens
Bedaquiline, Pretomanid, Moxifloxacin - Multi-drug Resistant Tuberculosis, Extensively Drug-Resistant Tuberculosis
Phase 2 / Phase 3CompletedMedecins Sans Frontieres, Netherlands732020-10-202024-04-22
Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)
Bedaquiline 100 MG, Delamanid 50 MG Oral Tablet, Clofazimine 100 MG Oral Capsule - Tuberculosis, Multidrug-Resistant, Tuberculosis
Phase 3CompletedMédecins Sans Frontières, France3232020-04-062025-02-10
Case Control Study of Vitamin D Status and Adult Multidrug-resistant Pulmonary Tuberculosis in Maharashtra, India
Serum Vitamin D - Multi-drug Resistant Tuberculosis
CompletedHarvard School of Public Health (HSPH)3522020-01-272021-02-25
Single-dose Study in Two Panels of Healthy Adult Participants to Assess Immediate-Release and Dispersible Formulations of Pretomanid
Pretomanid - Multi-drug Resistant Tuberculosis
Phase 1CompletedGlobal Alliance for TB Drug Development482020-01-142024-07-24
Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care
Bedaquiline Oral Tablet, Linezolid Oral Tablet, Delamanid in Oral Dosage Form - Tuberculosis, Pre-XDR-TB
Phase 3CompletedWits Health Consortium (Pty) Ltd4022019-08-222024-08-28
PRACTECAL-PKPD Sub Study
Bedaquiline, Pretomanid, Moxifloxacin - Multi-drug Resistant Tuberculosis, Extensively Drug-Resistant Tuberculosis
Phase 2 / Phase 3UnknownMedecins Sans Frontieres, Netherlands2402019-08-062021-05-14
Safety, Tolerability, Pharmacokinetics and Food Effects Study of PBTZ169
PBTZ169 640 mg OD, PBTZ169 640 mg BiD, PBTZ169 960 mg SD - Healthy Subjects
Phase 1CompletedNearmedic Plus LLC602018-07-032020-02-28
Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis
Pretomanid, Linezolid, Bedaquiline - Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant
Phase 3CompletedGlobal Alliance for TB Drug Development1812017-11-212023-06-29
Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)
Bedaquiline, Pretomanid, Moxifloxacin - Tuberculosis, Multidrug-Resistant, Extensively Drug-Resistant Tuberculosis
Phase 2 / Phase 3CompletedMedecins Sans Frontieres, Netherlands5522017-01-012024-05-01
An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis
Linezolid, Bedaquiline, Levofloxacin - Tuberculosis, Multidrug Resistant Tuberculosis
Phase 2 / Phase 3CompletedUniversity of Cape Town1542015-11-122021-09-29
A Phase 3 Trial Assessing Safety and Efficacy of B-Pa-L in Participants With DR-TB
Bedaquiline, PA-824, Linezolid - Pulmonary Tuberculosis
Phase 3CompletedGlobal Alliance for TB Drug Development1092015-03-012025-09-08
Global Consortium for Drug-resistant Tuberculosis Diagnostics
Tuberculosis, Tuberculosis, Multidrug-Resistant
CompletedUniversity of California, San Diego11282012-04-012014-06-23
Drug Interaction Study Between Linezolid and Clarithromycin in Tuberculosis Patients
Addition of different doses of clarithromycin. - Multidrug-resistant Tuberculosis, Extensively Drug-resistant Tuberculosis
Phase 4CompletedUniversity Medical Center Groningen72011-12-012013-07-01
Training Protocol on the Natural History of Tuberculosis
Mycobacterium Infections, Tuberculosis, Multidrug-Resistant
RecruitingNational Institute of Allergy and Infectious Diseases (NIAID)1502011-06-302026-11-10
Utility of MODS for Diagnosis of MDR-TB and Second-Line Antituberculous Drug Susceptibility Testing in Mali
Tuberculosis, Pulmonary, Mycobacterium Tuberculous
TerminatedNational Institute of Allergy and Infectious Diseases (NIAID)342011-05-312018-04-05
Tuberculosis in China
Tuberculosis, Tuberculosis, Multidrug-Resistant
CompletedNational Institute of Allergy and Infectious Diseases (NIAID)1992010-02-022018-04-05
Safety and Efficacy of Oral Immunomodulator in Tuberculosis (TB) and TB/HIV Patients
V-5 immunitor - Tuberculosis
Phase 2CompletedLisichansk Regional Tuberculosis Dispensary1232010-01-012012-08-03
Adjunct Immunotherapy With Immunoxel in Patients With TB and TB/HIV
Immunoxel, Placebo - Tuberculosis, HIV
Phase 3CompletedLisichansk Regional Tuberculosis Dispensary2692010-01-012015-05-20

Showing 20 of 23. Sign in to see all of them.

Narrower conditions

Tuberculosis, Multidrug-Resistant (22)  ·  Tuberculosis (17)  ·  Tuberculosis, Pulmonary (10)  ·  Mycobacterium Infections (3)  ·  Latent Tuberculosis (2)  ·  Anemia (1)  ·  Bacterial Infections (1)  ·  Gram-Positive Bacterial Infections (1)  ·  Optic Nerve Diseases (1)  ·  Peripheral Nervous System Diseases (1)  ·  Thrombocytopenia (1)  ·  Tuberculosis, Extrapulmonary (1)  ·  Vitamin D Deficiency (1)

Broader conditions

Actinomycetales Infections (23)  ·  Bacterial Infections and Mycoses (23)  ·  Infections (23)  ·  Bacterial Infections (22)  ·  Gram-Positive Bacterial Infections (22)  ·  Mycobacterium Infections (20)  ·  Lung Diseases (10)  ·  Respiratory Tract Diseases (10)  ·  Respiratory Tract Infections (10)  ·  Tuberculosis (6)  ·  Latent Infection (2)  ·  Avitaminosis (1)  ·  Blood Platelet Disorders (1)  ·  Cranial Nerve Diseases (1)  ·  Cytopenia (1)

Interventions

Linezolid (10)  ·  bedaquiline (9)  ·  pretomanid (7)  ·  Clofazimine (5)  ·  Moxifloxacin (5)  ·  OPC-67683 (3)  ·  Levofloxacin (2)  ·  Pyrazinamide (2)  ·  BID protein, human (1)  ·  Clarithromycin (1)  ·  Diet (1)  ·  Dosage Forms (1)  ·  Ethionamide (1)  ·  Isoniazid (1)  ·  Kanamycin (1)

Sponsors

Global Alliance for TB Drug Development (4)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (4)  ·  Medecins Sans Frontieres, Netherlands (3)  ·  Lisichansk Regional Tuberculosis Dispensary (2)  ·  Centers for Disease Control and Prevention (1)  ·  Centre for the AIDS Programme of Research in South Africa (1)  ·  Harvard School of Public Health (HSPH) (1)  ·  Médecins Sans Frontières, France (1)  ·  Nearmedic Plus LLC (1)  ·  Otsuka Pharmaceutical Development & Commercialization, Inc. (1)  ·  University Medical Center Groningen (1)  ·  University of California, San Diego (1)  ·  University of Cape Town (1)  ·  Wits Health Consortium (Pty) Ltd (1)

Countries

South Africa (11)  ·  United States (4)  ·  Belarus (3)  ·  India (3)  ·  China (2)  ·  Georgia (2)  ·  Moldova (2)  ·  Peru (2)  ·  Russia (2)  ·  South Korea (2)  ·  Ukraine (2)  ·  Uzbekistan (2)  ·  Egypt (1)  ·  Estonia (1)  ·  Ethiopia (1)

Top investigators

Antonio Lombardi, MD (2)  ·  Antonino Catanzaro, MD (1)  ·  Bern Nyang'wa, MB BS, MPH (1)  ·  Bern-Thomas Nyang'wa, MD (1)  ·  Carole Mitnick, Sc.D (1)  ·  Clifton Barry, Ph.D. (1)  ·  Clifton E Barry, Ph.D. (1)  ·  Dmytro Butov, MD (1)  ·  Francesca Conradie (1)  ·  Francesca Conradie, MD (1)  ·  Francesca M Conradie (1)  ·  Jan-Willem C Alffenaar, PhD, PharmD (1)  ·  Jussi Saukkonen, MD (1)  ·  Keertan Dheda, MBChB (1)

Results publications

PMID 27868466, PMID 21182457, PMID 22397570, PMID 22401633, PMID 22670901, PMID 23075177, PMID 23131255, PMID 23520311, PMID 25377177, PMID 27090176, PMID 27576542, PMID 28381434, PMID 28404672, PMID 28424085, PMID 28475735, PMID 29499645, PMID 31932382, PMID 32130813, PMID 33184081, PMID 34489274, PMID 34604901, PMID 35175905, PMID 35698158, PMID 36053506, PMID 36180816, PMID 36546625, PMID 36804834, PMID 37980911, PMID 38037119, PMID 38842323, PMID 39609025, PMID 39618688, PMID 40683298, PMID 41917253, PMID 42270675, PMID 42341301, PMID 42429813

NIH funding

U01AI082229 (1)